Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Prostatic Neoplasms 33Breast Neoplasms 23Stomach Neoplasms 16Squamous Cell Carcinoma of Head and Neck 15Lung Neoplasms 15Esophageal Neoplasms 13Neoplasm Metastasis 11Sarcoma 9Neoplasms 9Colorectal Neoplasms 7Urinary Bladder Neoplasms 6Ovarian Neoplasms 6Head and Neck Neoplasms 6Carcinoma, Transitional Cell 6Carcinoma, Renal Cell 6Melanoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Carcinoma, Ovarian Epithelial 4Breast Neoplasms, Male 4Salivary Gland Neoplasms 3Prostatic Neoplasms, Castration-Resistant 3Pancreatic Neoplasms 3Non-Muscle Invasive Bladder Neoplasms 3Leiomyosarcoma 3Inflammatory Breast Neoplasms 3Endometrial Neoplasms 3Carcinoma, Squamous Cell 3

Interventions

Prednisone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Castrate-Resistant Prostate Cancer × Docetaxel × Clear all
NCT01234025 2023-10-06

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Ionis Pharmaceuticals, Inc.

Phase 1/2 Completed
113 enrolled
Genitourinary

Castrate-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡